MitoSwab. Very happy with their reports. Not only looks at your level of mitochondrial activity but also channel efficiency.
Chad Lerner is fun to talk to
2 Likes
Interesting⊠launched this past summer, and sounds like its more for research than personal use:
VersĂ©a Discovery, Inc. Announces the Official Launch of mescreenâą Research Validator â a Revolutionary Mitochondrial Compound Assessment Platform
August 27, 2024 06:00 AM Eastern Daylight Time
TAMPA, Fla.âBUSINESS WIREâVersĂ©a Discovery, Inc., a Florida-based company dedicated to advancing scientific research and development in the area of personalized and precision medicine, has announced the official launch of mescreenâą Research Validator.
The mescreenâą Research Validator is a groundbreaking, proprietary compound assessment platform that harnesses mitochondrial function and dynamics to generate critical data, supporting the development, formulation, and clinical validation of customersâ supplements, nutraceuticals, pharmaceuticals, biologics, and medical devices.
By utilizing patented optimized bioassay, imaging, and machine-learning process, the mescreenâą Research Validator delivers valuable insights into mitochondrial efficiency and the clinical effects of various test materials in-vitro and in-vivo.
Research utilizing VersĂ©aâs proprietary machine learning system has analyzed over 60 FDA-approved compounds and probes known to impact mitochondrial function and dynamics. These studies have demonstrated the platformâs capability to detect changes in mitochondrial function and structure upon the introduction of test materials into the assay. The platform is also able to detect changes in mitochondrial function when therapeutics, interventions and lifestyle changes were introduced to and implemented by subjects.
âWe are thrilled to bring this groundbreaking technology to market,â said Stephen Porada, the President of VersĂ©a Discovery, Inc. âmescreenâą Research Validator has tremendous potential to help companies validate or optimize the performance of their bioactive molecules, ingredients or physical interventions being targeted for commercial product development.â
Dr. Hemal Patel, Chief Scientific Advisor of VersĂ©a Discovery, Inc., added, âIn addition to this important advancement, we are currently developing the mescreenâą Personalized Mitochondrial Efficiency Test, which aims to provide individuals with a comprehensive energetic profile. This test will utilize a 12-matrix panel to accurately quantify core functions and dynamics providing important data and information related to oneâs mitochondrial efficiency. Our commitment to enhancing mitochondrial health will empower individuals to better understand and improve their well-being.â
To gain insight into the science behind mescreen⹠Research Validator and explore how it can benefit your research and product development efforts, please contact Verséa Discovery, Inc. at discovery@versea.com or call 1-800-397-0670.
About Verséa Discovery, Inc.
Verséa Discovery, Inc., headquartered in Tampa, FL, is a U.S. company committed to advancing scientific research and development in personalized and precision medicine. Operating as a strategic business unit of Verséa Health, Inc., the company specializes in developing innovative solutions that deliver critical insights into health at the cellular and mitochondrial levels. To learn more visit Verséa Discovery webpage.
Disclaimer: mescreen⹠is for research use only and is not intended to diagnose, treat, or cure disease. You should not change medications, diet, exercise regimens, or other related health activities without consulting your physician. mescreen⹠has not been reviewed by the Food and Drug Administration. mescreen⹠is a trademark of Verséa Health, Inc.
1 Like
I checked this company months ago as they have (had?) a lactoferrin test that could be used for the early diagnosis of Parkinsonâs and/or Alzheimerâs. That test was very serious. I donât know about this new mitochondria test though.
1 Like
https://x.com/trikomes/status/1924906797200245138
The dashboard youâre looking at is not an organic-acids profile.
It comes from a direct enzyme-activity panel that the lab runs on the mitochondria-containing cells in your blood sample (mostly platelets and leukocytes). In each well of a micro-plate the lab:
- immuno-captures one respiratory-chain complex (or citrate-synthase as a reference),
- adds a very specific substrate/cofactor mix, and
- follows the initial reaction rate by watching a change in light absorbance.
What is being quantified in each well is therefore an enzyme-catalysed reaction rate, not a circulating metabolite.
Here are the actual reactions and the âreporterâ signals the spectroÂphotometer tracks:
| Report line | Enzyme reaction in the assay well | Spectral âreporterâ that is monitored |
|---|---|---|
| Complex I (NADH dehydrogenase) | NADH â NADâș + Hâș (electrons passed to ubiquinone analogue) | Disappearance of NADH at 340 nm |
| Complex II (Succinate dehydrogenase) | Succinate â fumarate (electrons to CoQ analogue) | Reduction of DCPIP or decyl-ubiquinone (600 nm) |
| Complex II + III (Succinate : cyt-c reductase) | Succinate â fumarate â cytochrome c (via complexes II & III) | Appearance of reduced cytochrome c at 550 nm |
| Complex IV (Cytochrome-c oxidase) | 4 Red-cyt-c + Oâ â 4 Ox-cyt-c + 2 HâO | Loss of reduced cytochrome c absorbance at 550 nm |
| Citrate-synthase (normalises for mito number) | Oxaloacetate + Acetyl-CoA â Citrate + CoA-SH | Formation of TNB from CoA-SH + DTNB at 412 nm |
So the only âanalytesâ the instrument is reading are:
- NADH (Complex I)
- DCPIP / ubiquinone analogue (Complex II)
- Reduced cytochrome c (Complex II + III and IV)
- TNB (Ellmanâs reagent product) for citrate-synthase
The green/orange gauges you see are simply each reaction rate normalised to citrate-synthase activity and then expressed as a percentage of a healthy-control mean. No plasma metabolites (lactate, succinate, organic acids, etc.) enter into these particular numbers.
2 Likes
Is that another mitochondrial test?
Mhi
Thank you for this. I had a full genome test suggesting that I have some degree of Complex I deficiency as well as an OAT test showing something similar. Would be cool to see it confirmed again here because I am not a genetics expert and didnât know what I was doing with the whole genome data.
I wonât be trying this though because I think the price is unreasonable. The cost of the full genome test and the OAT test combined was still much less than this. Iâll keep my eye out for similar tests.
This is a test I heard of a while back: https://www.iollo.com/
Pricy, but still less than the Mescreen. Canât vouch for it other than I heard of it years ago and bookmarked it.
Itâs just a cheek swab, I really donât know if it can be this informativeâŠ
Only $700 though. I like Chris and even subscribed for a couple years, but donât know about this.
The Mitome test had showed that this client had impaired transport of methyl groups into the mitochondria, and since creatine supports methylation, this may have made him respond especially well to the creatine. However, everyone needs to optimize their creatine status so this is a safe and fruitful path to embark on without testing first.
Mitome reflects a year and a half of deep research into the causes of many different patterns of mitochondrial dysfunction, fused with my own cross-referencing over 100 sets of respiratory chain data with comprehensive whole genome sequencing and biochemical data (amino acids, organic acids, vitamins, minerals, and other markers) to distill ways of inferring causal patterns and effective actionable protocols from repeatable patterns within the respiratory chain data when used on its own. Mitome uses a cheek swab to measure each of the four respiratory chain complexes where 90% of your cellular energy (ATP) is made to infer which of 12 âmitochondrial typesâ you are and how your patterns combine into one of 90 unique approaches to personalizing your strategies to boost your cellular energy production. Mitome also simplifies this for you by automatically constructing your protocol for you. Find out your mitochondrial type today with Mitome.
Short answer: partly.
Whatâs solid: Mitomeâs cheek-swab labwork appears to be run on/with the MitoSwab platform. Buccal (cheek) cells can be used to measure mitochondrial enzyme activities (e.g., Complex I, III, IV) and citrate synthase, and thereâs peer-review showing these buccal assays track muscle-biopsy enzyme defects ~82% of the time for Complex I/IV in confirmed mitochondrial disease (small, pediatric cohort).
Whatâs iffy: Mitome markets a personalized âoptimization protocolâ from those cheek-cell readings. That interpretive algorithm and clinical benefit (e.g., better symptoms/outcomes because you followed their supplement/diet plan) havenât been validated in published trials, and the underlying test is a CLIA LDT, not FDA-cleared. Price listed is $699.
The âonly cheek cellsâ concern (youâre right)
Mitochondria vary a lot by tissue (proteins, assembly, morphology, fuel use). Cheek epithelium is not a stand-in for brain, heart, liver, or skeletal muscle. Also, buccal epithelium turns over fast (~14 days), so a swab reflects recent state and local exposures (diet, smoke/vape, oral inflammation), not âwhole-body mitochondrial health.â
What Mitome says it measures
Their page lists citrate synthase plus Complex I, II, II+III, and IV from a cheek swab; they then generate food/supplement suggestions. (Note: âII+IIIâ is an activity assay, not a single complex.)
How good are cheek-swab enzyme assays?
Pros: Non-invasive; methods exist for CI/CIII/CIV. One 2012 study reported ~82.5% correlation with muscle biopsy for CI/IV in diagnosed cases; a 2023 paper details buccal Complex III assays.
Caveats: Small cohorts; CI/IV most studied; diet/smoking can modulate buccal mitochondrial readouts; and results may not mirror high-energy tissues. The test is not diagnostic on its own.
If you want a more âsystemicâ readout
Some groups measure mitochondrial respiration in blood cells (PBMCs/platelets) and show links to muscle and clinical states, but these, too, have confounders (immune-cell mix, methods) and are mostly research-setting.
Practical take
Consider Mitome as a screening/monitoring tool, not a verdict on body-wide mitochondria.
If you do it, standardize pre-collection: follow their instructions (rinse with water; wait 30 min after brushing; ship MonâThu on ice) and avoid acute confounders (smoking/vaping right before sampling).
For organ-specific symptoms (e.g., neuromuscular issues), see a specialist; gold-standard workups still rely on targeted clinical testing.
Bottom line: The measurement part (cheek-cell enzyme activities) has some peer-reviewed support; the âpersonalized protocolâ part is not clinically validated. Treat Mitome as potentially informative but non-diagnostic, and be cautious about over-interpreting cheek-cell data as your global mitochondrial status.
1 Like
I got my results back. They were very simple. I guess I need to supplement with CoQ and also it may be better for me to stay away from statins.
(and MAYBE i might benefit from methylene blue)
Complex I
Normal
136%Complex II
Normal
107%Complex II + III
Low
23%Complex IV
Normal
80%Citrate Synthase
High-Normal
171%Results Summary
Your mitochondrial complex II + III activity is at 23% of normal function. These
enzyme complexes are critical components in the electron transport chainâthe
cellular pathway that produces most of your ATP (energy). This blockage impairs
your cellsâ ability to metabolize all fuel types. The dysfunction substantially
reduces your energy production, affecting both your daily performance and your
bodyâs capacity to maintain long-term health functions.
Overall, this means you may benefit from CoQ10, vitamin C, vitamin K2 (in the
form of MK-4), sulfur amino acids, near infrared light in the 700-1000 nanometer
range, methylene blue, and the removal of complex III inhibitors from your diet,
lifestyle practices, and medications.
===
The table below gives normal ranges based on 95% confidence intervals in control samples. Your
percentages listed on the previous page are a percentage of the mean control. For example, if your
citrate synthase was â100%,â you can derive its activity in nanomoles per minute per milligram buccal
protein by multiplying 100% times 12.1 in the below table, meaning it was operating at 12.1 nanomoles
per minute per milligram buccal protein. You can then compare that to the normal range and conclude
that it is normal.
Due to the lack of large sample sizes and associated statistical precision in these normal ranges, the
Mitome analysis categorizes results as a percentage of control means into normal (70-140%), low (â€
50%), high (â„ 200%), or low or high normal between these ranges, based on standardized cutoffs for
the sake of optimal pattern analysis. This is the basis for the descriptors you see on the previous page
and for any patterns we derive from those descriptors.
Enzyme Normal Ranges and Mean Activities
Activity Name Normal Range Mean ± SD
Citrate Synthase (CS) 4.4-22 12.1 ±5.1
Complex I
(normalized to CS)3.4- 11.9
6.8 ±2.0Complex II
(normalized to CS)0.03-0.35
0.194 ±0.08Complex II + III
(normalized to CS)0.032-0.152 0.092 ±0.03
Complex IV
(normalized to CS)0.15- 0.6 0.31 ±0.1
1 Like
Got it. I converted your Mitome percentages to the underlying values using the reportâs own rule:
raw value = (your %) Ă (control mean) / 100.
Iâm keeping the original units exactly as the table states. For the complexes, the ârawâ unit is the activity normalized to citrate synthase (a unitless ratio, by assay convention). Citrate synthase (CS) is in nmol/min/mg buccal protein.
Raw values (from your percentages)
Assay Your % of control mean Control mean Raw value Reference range Citrate Synthase (CS) 171% 12.1 nmol/min/mg 20.7 nmol/min/mg 4.4â22 nmol/min/mg Complex I (normalized to CS) 136% 6.8 9.25 3.4â11.9 Complex II (normalized to CS) 107% 0.194 0.208 0.03â0.35 Complex II + III (normalized to CS) 23% 0.092 0.0212 0.032â0.152 Complex IV (normalized to CS) 80% 0.31 0.248 0.15â0.60 Notes: values rounded to 3 significant figures. âNormalized to CSâ is a dimensionless ratio per the labâs method.
Optional: absolute activities for the complexes (nmol/min/mg), assuming ânormalized to CSâ = complex rate / CS rate
If we take your CS rate as 20.7 nmol/min/mg and multiply by each normalized ratio, we get approximate absolute rates for the complexes:
- Complex I â 191.35 nmol/min/mg
- Complex II â 4.295 nmol/min/mg
- Complex II + III â 0.4378 nmol/min/mg
- Complex IV â 5.131 nmol/min/mg
Caveat: labs typically interpret complexes via the CS-normalized ratios, not these derived absolutes. Iâm showing them because the math is straightforward and sometimes useful for cross-assay comparisons, but clinical interpretation usually sticks to the normalized numbers.
If you want this as a CSV for your notes, say so and Iâll spit it out.
===
Short answer: a choke point at complex II+III can hit both ATP and ROS. Itâs not just âlow energy.â When electrons pile up before complex III, they leak. Leaky electrons make superoxide, especially at complex IIIâs Qo site. Chronic over-reduction there is linked to redox stress, hypoxia signaling, and downstream damage. So yes, this pattern can contribute to aging biology via ROS signaling, not only fatigue.
Hereâs how Iâd think about fixes, in order of âlikely to help / low regretâ:
1) Treat this like a Q-junction bottleneck
Your isolated drop in âcomplex II+IIIâ with normal II, I, and IV is the classic footprint of a coenzyme Q (CoQ) bottleneck: the assay literally depends on II handing electrons to CoQ which then feeds III. If the Q-pool is thin or sluggish, II+III reads low even when II and III themselves test fine. That exact pattern is widely reported in CoQ deficiency workups, which is why labs use the I+III and II+III âsegmentsâ as CoQ-dependent screens.
Practical next steps:
- Measure CoQ10 status with a clinically useful matrix. Plasma is common but tracks lipoproteins; leukocytes/fibroblasts or muscle are better if youâre going for precision. If itâs low or borderline, you have a clean target.
- Scan meds/exposures that punish the Q-junction or complex III:âą Statins consistently lower circulating CoQ10. Not a hard stop, but itâs a confounder and a reason to supplement if you must stay on them.âą Atovaquone is a bona fide complex III inhibitor.If either applies, thatâs low-hanging fruit.
2) Core interventions
CoQ10 (prefer ubiquinol): despite mixed RCTs, mitochondrial guidelines still recommend offering CoQ10 given mechanism, safety, and case-level benefits. Typical adult doses used clinically are 200â600 mg/day with fat, often split. Recheck symptoms and, if you want to be data-driven, re-measure a CoQ marker or repeat the buccal assay after 8â12 weeks.
Riboflavin (B2): supports FAD-dependent complex II flux feeding the Q-pool. Common mitochondrial doses are 100â200 mg/day. Evidence base is small/open-label, but the risk is low.
Photobiomodulation (near-IR ~670â850 nm): repeatedly shown to upregulate cytochrome c oxidase activity and improve mitochondrial performance, with aging-offset effects in animal and human studies. If you use it, think small spot size, a few minutes per site, several times per week.
Antioxidant/GSH support: Vitamin C, alpha-lipoic acid, and sulfur amino acids/N-acetylcysteine help control the ROS spillover while you fix throughput. This is standard supportive care in mitochondrial medicine, even if hard outcome trials are scarce.
Training, not overtraining: Zone-2 aerobic plus resistance training expands mitochondrial content and capacity, which raises headroom at the same load. Start modestly if youâre symptomatic and progress weekly. This is boring, but it compounds. (General principle from mitochondrial rehab literature.)
3) Where methylene blue and metformin fit
Methylene blue (MB): cautiously promising, with caveats.
Low-dose MB can accept electrons upstream and donate directly to cytochrome c, effectively creating a side-route that lessens traffic through IâQâIII. In models it enhances respiration, raises ATP, and lowers ROS when dosed low. Translation: it can relieve the pressure that makes complex III leak. But it will not ârepairâ a depleted Q-pool, and evidence is mixed on whether MB truly bypasses a hard complex III block in living cells. If you try it, do it supervised.
Safety you should actually care about: MB is a MAOI at clinically relevant doses. It can precipitate serotonin syndrome with SSRIs/SNRIs/TCAs, and G6PD deficiency is a red flag. Typical brain/mito protocols use low oral doses (e.g., ~10â30 mg/day, sometimes titrated), but you clear this with a clinician who knows your meds and labs.
Metformin: probably not your friend for this goal.
Metformin inhibits complex I. In the general T2D population, lactic acidosis is rare, but in mitochondrial disease circles itâs on the âuse cautiously or avoid if possibleâ list because it can worsen oxidative phosphorylation and lactate handling. If your priority is energy and you already have a downstream choke, adding an upstream brake is⊠unhelpful. If you need glycemic control, choose alternatives and decide with your doc.
4) Vitamin K2 (MK-4) reality check
Cool Drosophila paper showed MK-4 acting as a mitochondrial electron carrier and rescuing pink1 phenotypes. Follow-up human cell work failed to replicate functional rescue. Bottom line: keep K2 for bones and maybe extrahepatic vitamin K biology, but donât expect it to replace CoQ in human mitochondria.
5) A simple, sane plan
- Confirm: get a CoQ10 level in a useful matrix; review meds for statins/atovaquone or other offenders.
- Correct: start CoQ10 (ubiquinol), add riboflavin; layer in PBM; use antioxidant/GSH support while throughput recovers.
- Consider MB only if your med list is clean for serotonergic risks and you have clinician oversight.
- Re-test in ~8â12 weeks to see if II+III normalized toward the 0.032â0.152 reference band. If it moves up, keep going; if it doesnât, escalate the workup.
Youâve basically got a Q-junction traffic jam. Clear the jam first (CoQ10, riboflavin, PBM, remove inhibitors), then decide if you want clever detours like MB. Metformin is the opposite of that. If you want, Iâll format this into a one-page protocol you can hand your clinician, minus the eye-rolls.
===
Short version: food can nudge your Q-junction, not bulldoze it. Still worth nudging.
What to eat to âunclogâ the IIâQâIII handoff
Think âsupport the Q-pool, feed SDH (complex II), and provide the metal/vitamin parts complex III needs.â
1) Support CoQ10 itself (the Q-pool)
- Eggs, pistachios, peanuts, sesame/tahini, soy have small but real CoQ10. You will not eat your way to therapeutic doses, but these help the baseline. Example numbers: ~2 mg/100 g pistachios, ~2.6 mg/100 g peanuts, ~1.7 mg/100 g sesame.
- Protein for the ring: your body builds CoQ10âs benzoquinone head from tyrosine/phenylalanine, and its tail via the mevalonate pathway. So adequate protein (eggs, soy, legumes) supports the ring, and not kneecapping the mevalonate pathway supports the tail.
- Nerd check: low II+III with normal II is a classic CoQ bottleneck signal on segment assays, i.e., electrons can leave succinate but stall at Q before III.
2) Feed complex II (SDH) cofactoring
- Riboflavin/B2 makes FAD for SDH. Ovo-veg sources: eggs, mushrooms, almonds, spinach, fortified cereals.
- Sulfur amino acids (for glutathione redox support): eggs; plus alliums and brassicas for sulfur chemistry. Not glamorous, actually useful.
3) Build complex IIIâs âhardwareâ
- Complex III contains heme b and a Rieske ironâsulfur protein. You need iron, vitamin B6 for heme synthesis, and a little copper to keep iron traffic and cytochrome c oxidase happy. Ovo-veg playbook:
- Iron: lentils, chickpeas, tofu, pumpkin seeds, spinach + vitamin-C produce to boost absorption.
- B6: potatoes, bananas, pistachios, sunflower seeds.
- Copper: cashews, sesame/tahini, cocoa powder.These arenât random âsuperfoodsâ; theyâre the parts bin for heme and Fe-S biology.
4) Antioxidant backstop while you fix throughput
- Vitamin C helps recycle the Q/antioxidant network; selenium supports GPx. One Brazil nut now and then covers selenium without detonating your calories. Meanwhile, keep ROS down where it starts: complex IIIâs Qo site loves to spit superoxide when the Q-pool is over-reduced.
So⊠is high succinate a clue?
Sometimes. If succinate is high (typically on a urine organic acids test), that can reflect SDH impairment or a downstream handoff problem that causes back-pressure. Succinate is also a signaling metabolite that inhibits prolyl-hydroxylases and stabilizes HIF-1α, which is cool in a paper and annoying in a person. But itâs not specific: microbiome output, hypoxia, hard exercise and other bottlenecks can raise it too. In your pattern (II normal, II+III low), a thin Q-pool can still let succinate creep up because SDH canât pass electrons to Q fast enough under load. Confirm with CoQ10 status rather than guessing from succinate alone.
Tiny, boring plan that actually works
- Daily: eggs or fortified cereal + leafy greens; legumes or tofu; a tablespoon of tahini or a small handful of pistachios or peanuts; vitamin-C produce with iron-rich meals.
- Weekly: one Brazil nut; mushrooms a few times; cocoa powder cameo if you want copper without a calorie avalanche.
- Supplement layer if youâre serious about moving the needle: ubiquinol CoQ10 and riboflavin remain the heavy lifters; food wonât replace them. Re-check your II+III after 8â12 weeks. The reason is biochemical, not vibes.
Side note, because biology has a sense of humor: when electrons pile up before III, ROS rises right there at complex III. Fixing the throughput tends to help both energy and aging-adjacent redox signaling, not just ATP.
If you want me to turn this into a 1-page grocery + lab checklist, Iâll do it without snark. For once.
1 Like
I have intermittently taken a few statins every 2 weeks, itâs possible those might be affecting the resultsâŠ
God, the mitome report was worth it in the end. Yes itâs $600, but $600 still is nothing compared to the insight you can get from this. Itâs very actionable, way more so than epigenetic age tests (still) are.
2 Likes
Short version: if your âQâ is low, Complex II canât hand off electrons efficiently, so flux through succinate dehydrogenase stalls and succinate tends to pile up. Raising the CoQ pool usually relieves that bottleneck and should lower succinate, as long as downstream steps (Complex III/IV) arenât the real choke point and SDH itself isnât mutated. (PNAS)
Why that happens, in human terms:
- Complex II oxidizes succinate to fumarate and passes the electrons to ubiquinone (CoQ). If the quinone pool is too small or too reduced, SDH forward flux slows and succinate accumulates. In hypoxia or when the Q pool is over-reduced, SDH can even run in reverse, further boosting succinate. (PNAS)
- Directly blocking the Q-binding site of Complex II is known to raise intracellular succinate; low CoQ is a physiological way of creating a similar âacceptor-limitedâ state. (Nature)
- Excess succinate isnât just clutter. It inhibits HIF prolyl-hydroxylases, stabilizes HIF-α, and perturbs dioxygenases tied to chromatin, nudging inflammatory and senescence-adjacent programs. (ScienceDirect)
Will more CoQ help? Often, yes:
- In CoQ deficiency, activities at the IIâIII segment drop and ROS rises; replenishing CoQ generally improves electron transport and redox balance. That should reduce succinate backlog if the primary issue is limited Q availability. (MDPI)
- Caveats: if Complex II itself is compromised (SDHx or assembly-factor defects), or Complex III/IV are impaired so the Q pool stays reduced, extra CoQ wonât fully fix succinate buildup. Context matters. (FEBS Journals)
If youâre trying to ground this in data rather than vibes:
- When clinicians investigate true CoQ problems, they donât rely on plasma alone; they look at tissue or cell assays (muscle, fibroblasts, or blood cells) and sometimes organic acids for succinate. Thatâs the route if you want a hard answer about your Q pool and succinate. (PMC)
Net: low CoQ can absolutely create a functional âQ blockade,â which favors succinate accumulation; restoring CoQ tends to relieve it, provided the rest of the chain can accept the flow. If youâre experimenting, be cautious and loop in a clinician; mitochondria reward precision, not guesswork.